Moderna vaccine mRNA-1273 tests positive immune system against coronavirus

New Delhi : An experimental vaccine (mRNA 1273) from the U.S. biotechnology company Moderna Inc. has shown signs of creating an immune system against the coronavirus, offering tentative hopes of being a cure vaccine from COVID 19 infection that has rattled the world.

The results are just a sample from the small, first study designed to look at the safety of the shot in human volunteers, and should be viewed with caution. So far no major safety worries have come up with the vaccine, a big relief for the company so far.

“This is a very good sign that we make an antibody that can stop the virus from replicating,” Moderna Chief Executive Officer Stephane Bancel said in an interview. The data “couldn’t have been better”, he said.

The company is now planning to increase the testing size and study its effectiveness. 

A vaccine is considered a crucial step toward lifting social-distancing measures and safely reopening economies, schools and events around the globe.

Around 5 million people have been infected with the virus so far and over 3 lakh people have lost their lives worldwide.

Moderna Market shares rose by 30%

Moderna shares surged as much as 30% in New York, hitting an all-time intraday high of $87. Broader markets rose as well, with the S&P 500 gaining 3.1% as the confident tone on vaccine candidates from Moderna, the University of Oxford and China added to confidence that scientists have the tools to stop the virus.